Genetic characterization of fluoro quinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis

被引：20

作者：

de la Campa, AG

Ferrandiz, MJ

Tubau, F

Pallarés, R

Manresa, F

Liñares, J

机构：

[1] CSIC, Ctr Nacl Microelect, Unidad Genet Bacteriana, Inst Salud Carlos III, E-28006 Madrid, Spain

[2] Bellvitge Hosp, Microbiol Serv, Barcelona, Spain

[3] Bellvitge Hosp, Serv Enfermedades Infecc, Barcelona, Spain

[4] Bellvitge Hosp, Serv Neumol, Barcelona, Spain

[5] Univ Barcelona, Hosp Llobregat, Barcelona, Spain

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2003年 / 47卷 / 04期

关键词：

D O I：

10.1128/AAC.47.4.1419-1422.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Five Spain(9V-3) Streptococcus pneumoniae strains were isolated from a patient with bronchiectasis who had received long-term ciprofloxacin therapy. One ciprofloxacin-susceptible strain was isolated before treatment, and four ciprofloxacin-resistant strains were isolated during treatment. The resistant strains were derived from the susceptible strain either by a parC mutation (low-level resistance) or by parC and gyrA mutations (high-level resistance). This study shows that ciprofloxacin therapy in a patient colonized by susceptible S. pneumoniae may select fluoroquinolone-resistant mutants.

引用

收藏

页码：1419 / 1422

页数：4

相关论文

共 35 条

[1] Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain:: Clonal diversity and appearance of ciprofloxacin-resistant epidemic clones [J].

Alou, L ;

Ramirez, M ;

García-Rey, C ;

Prieto, J ;

de Lencastre, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2955-2957

[2] Molecular characterization of the gene encoding the DNA gyrase a subunit of Streptococcus pneumoniae [J].

Balas, D ;

Fernández-Moreira, E ;

De la Campa, AG .

JOURNAL OF BACTERIOLOGY, 1998, 180 (11) :2854-2861

[3] Community-acquired pneumonia in adults: Guidelines for management [J].

Bartlett, JG ;

Breiman, RF ;

Mandell, LA ;

File, TM .

CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :811-838

[4]

Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954

[5] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].

Chen, DK ;

McGeer, A ;

de Azavedo, JC ;

Low, DE .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239

[6] Adaptation to the environment:: Streptococcus pneumoniae, a paradigm for recombination-mediated genetic plasticity? [J].

Claverys, JP ;

Prudhomme, M ;

Mortier-Barrière, I ;

Martin, B .

MOLECULAR MICROBIOLOGY, 2000, 35 (02) :251-259

[7] Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. [J].

Davidson, R ;

Cavalcanti, R ;

Brunton, JL ;

Bast, DJ ;

de Azavedo, JCS ;

Kibsey, P ;

Fleming, C ;

Low, DE .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) :747-750

[8] DNA gyrase, topoisomerase IV, and the 4-quinolones [J].

Drlica, K ;

Zhao, XL .

MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) :377-+

[9] Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins [J].

Fernández-Moreira, E ;

Balas, D ;

González, I ;

de la Campa, AG .

MICROBIAL DRUG RESISTANCE, 2000, 6 (04) :259-267

[10] Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci [J].

González, I ;

Georgiou, M ;

Alcaide, F ;

Balas, D ;

Liñares, J ;

De la Campa, AG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2792-2798

← 1 2 3 4 →